Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eduardo Ibarra

Pain Medicine Aibonito, PR Medical Doctor

NPI 1871539932 CMS profile 175119

204 Calle Julio Cintron, Suite 224, Aibonito, PR 00705

Open in the dashboard

General payments

$329,073

346 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$143,457 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Eduardo Ibarra of Aibonito, PR is reported in the CMS Open Payments database as having received $329,073 across 346 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $143,457 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $57,341 72
2024 General $21,783 25
2023 General $35,925 27
2022 General $46,643 25
2021 General $37,780 26
2020 General $23,976 48
2019 General $105,626 123

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eduardo Ibarra
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Eduardo Ibarra were reported at $57,341. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Eduardo Ibarra Pain Medicine median Middle half National median
2019 $105,626 $498 $126–$1,682 $163
2020 $23,976 $284 $80–$910 $114
2021 $37,780 $399 $112–$1,219 $132
2022 $46,643 $455 $137–$1,484 $149
2023 $35,925 $484 $128–$1,495 $160
2024 $21,783 $498 $131–$1,540 $164
2025 $57,341 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $146,588 171 payments
  2. Medtronic USA, Inc. $93,448 26 payments
  3. Abbott Laboratories $46,652 65 payments
  4. Boston Scientific Corporation $42,384 84 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $152,121 50 payments
  2. Consulting Fee $145,340 32 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $20,265 5 payments
  4. Food and Beverage $5,974 250 payments
  5. Travel and Lodging $4,174 8 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $1,200 1 payment
Products named General payments · program years 2019–2025
  1. ADAPTIVESTIM $68,316 17 payments
  2. WaveWriter Alpha Prime 16 $31,951 36 payments
  3. Proclaim Family of SCS IPGs $24,899 24 payments
  4. INTELLIS $16,147 19 payments
  5. PROCLAIM Structural Heart $15,802 7 payments
  6. LIORESAL $8,280 2 payments
  7. INTELLIS ADAPTIVESTIM $6,417 14 payments
  8. CLINICAL TRIAL PRODUCT $5,097 2 payments
  9. PROCLAIM Neuromodulation $3,600 1 payment
  10. SPECTRA WAVEWRITER $3,000 1 payment
  11. Other $11,304 197 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

542

Median for Interventional Pain Management: 1,220

Drug cost

$9,039

Median for Interventional Pain Management: $39,344

Branded share of claims

42.1%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 217 $2,938
Cefadroxil Generic 107 $2,012
Lidocaine Generic 11 $1,516
Tramadol Hcl Generic 132 $888
Oxycodone Hcl Generic 12 $820
Gabapentin Generic 34 $512
Methylprednisolone Generic 18 $197
Endocet Oxycodone Hcl/Acetaminophen Brand 11 $157

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$8,948

Medicare's payments for the services billed

Medicare patients

14

Average age 75

Services billed

55

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Arthritis 75%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

346 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record